Novel C5-dependent mechanism of neutrophil stimulation by bioincompatible dialyzer membranes

Journal of the American Society of Nephrology

Volumn 10, Issue 1, 1999, Pages 128-135

  Rosenkranz, Alexander R ^b   Körmöczi, Günther F ^b   Thalhammer, Florian ^b   Menzel, Ernst J ^b   Hörl, Walter H ^b   Mayer, Gert ^b   Zlabinger, Gerhard J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5; CUPROPHANE; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ARTICLE; ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; DIALYSIS MEMBRANE; FEMALE; HEMODIALYSIS; HUMAN; LEUKOCYTE ACTIVATION; MALE; PATIENT CODING; PRIORITY JOURNAL; RECEPTOR BINDING; RESPIRATORY BURST;

EID: 0344959645     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS: Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 296: 769-774, 1977
2. Craddock PR, Fehr J, Dalmasso AP, Brigham KL, Jacob HS: Hemodialysis leukopenia: Pulmonary vascular leukostasis resulting from complement activation by dialyser cellophane membrane. J Clin Invest 59: 879-888, 1977
3. Chenoweth DE, Cheung AK, Henderson LW: Anaphylatoxin formation during hemodialysis: Effect of different dialyser membranes. Kidney Int 24: 764-769, 1983
4. Hakim RM, Breillatt J, Lazarus JM, Port FK: Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 311: 878-882, 1984
5. Cheung AK, Parker CJ, Wilcox L, Janatova J: Activation of the alternative pathway of complement by cellulosic hemodialysis membranes. Kidney Int 36: 257-265, 1989
6. Descamps-Latscha B, Goldfarb B, Nguyen AT, Landais P, London G, Haeffner-Cavaillon N, Jacquot C, Berbelin A, Kazatchkine M: Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: A randomized prospective study. Nephron 50: 279-285, 1991
7. Pertosa G, Tarantino EA, Gesualdo L, Montinaro V, Schena FP: C5b-9 generation and cytokine production in hemodialyzed patients. Kidney Int 43: S221-S225, 1993
8. Lee J, Hakim RM, Fearon DT: Increased expression of the C3b receptor by neutrophils and complement activation during hemodialysis. Clin Exp Immunol 56: 205-214, 1984
9. Arnaout MA, Hakim RM, Todd RF, Dana N, Colten HR: Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 312: 457-462, 1985
10. Grooteman MPC, Bos JC, van Houte AJ, van Limbeck J, Schoorl M, Nubé ME: Mechanisms of intra-dialyser granulocyte activation: A sequential dialyser elution study. Nephrol Dial Transplant 12; 492-499, 1997
11. Himmelfarb J, Zaoui P, Hakim R: Modulation of granulocyte LAM-1 and Mac-1 during dialysis: A prospective, randomized controlled trial. Kidney Int 41: 388-398, 1992
12. Alvarez V, Pulido R, Campanero MR, Parai so V, De Landozuri MO, Sanchez-Madrid F: Differentially regulated cell surface expression of leukocyte adhesion receptors on neutrophils. Kidney Int 40: 899-905, 1991
13. Rabb H, Agosti SJ, Bittle PA, Fernandez, M, Ramirez G, Tedder TF: Alterations in soluble and leukocyte surface L-selectin (CD62L) in hemodialysis patients. J Am Soc Nephrol 6: 1445-1450, 1995
14. Haeffner-Cavaillon N, Cavaillon JM, Ciancioni C, Bade F, Delons S, Kazatchkine MD: In-vivo induction of interleukin-1 during hemodialysis. Kidney Int 35: 1212-1218, 1989
15. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B: Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α. Kidney Int 37: 116-125, 1990
16. Lonnemann G, Bingel M, Floege J, Koch KM, Shaldon S, Dinarello CA: Detection of endotoxin-like interleukin-1 inducing activity during in vitro dialysis. Kidney Int 33: 29-35, 1988
17. Luger A, Kovarik J, Stummvoll HK, Urbanska A, Luger TA: Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 32: 84-88, 1987
18. Betz M, Haensch GM, Rauterberg EW, Bommer J, Ritz E: Cuproammonium membranes stimulate interleukin-1 release and arachidonic acid metabolism in monocytes in the absence of complement. Kidney Int 34: 67-73, 1988
19. Hörl WH, Steinhauer HB, Schollmeyer P: Plasma levels of granulocyte elastase during hemodialysis: Effects of different dialyzer membranes. Kidney Int 28: 791-796, 1985
20. Hörl WH, Riegel W, Schollmeyer P, Rautenberg W, Neumann S: Different complement and granulocyte activation in patients dialyzed with PMMA dialyzers. Clin Nephrol 25: 304-307, 1986
21. Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B: Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 28: 158-167, 1985
22. Himmelfarb J, Lazarus JM, Hakim R: Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 17: 271-276, 1991
23. Himmelfarb J, Ault KA, Holbrook D, Leeber DA, Hakim RM: Intradialytic granulocyte reactive oxygen species production: a prospective, crossover trial. J Am Soc Nephrol 4: 178-186, 1993
24. Rosenkranz AR, Tempi E, Traindl O, Heinzl H, Zlabinger GJ: Reactive oxygen product formation by human neutrophils as an early marker for biocompalibility of dialysis membranes. Clin Exp Immunol 98: 300-305, 1994
25. Vogt W: Complement activation by myeloperoxidase products released from stimulated human polymorphonuclear leukocytes. Immunobiology 195: 334-346, 1996
26. Bass DA, Parce JW, Deehatelet LR, Szejda P, Seeds MC, Thomas M: Flow cytometric studies of oxidative product formation by neutrophils: A graded response to membrane stimulation. J Immunol 130: 1910-1917, 1983
27. Tetteroo PA, Bos MJ, Visser FJ, von dem Borne AE: Neutrophil activation detected by monoclonal antibodies. J Immunol 136: 3427-3432, 1986
28. Majdic O: Cluster report: CD66. In: Leukocyte Typing IV, edited by Knapp W, New York, Oxford University Press, 1989, pp 838-840
29. Kuijpers TW, Van der School CE, Hoogerwerf M, Roos D: Cross-linking of the carcinoembryonic antigen-like glycoproteins CD66 and CD67 induces neutrophil aggregation. J Immunol 151: 4934-4940, 1993
30. Himmelfarb J, McMonagle E, Holbrook D, Toth C: Soluble complement receptor 1 inhibits both complement and granulocyte activation during ex vivo hemodialysis. J Lab Clin Med 126: 392-400, 1995
31. Sengelov H: Complement receptors in neutrophils. Crit Rev Immunol 15: 107-131, 1995
32. Oppermann M, Raedt U, Götze O: Peptide-specific antibodies that react with the C5a receptor and antagonize C5a/C5a (des-Arg) biological activity. In: Leukocyte Typing V, edited by Schlossmann SF, New York, Oxford University Press, 1995, pp 955-956
33. Fraticelli A, Serrano CV Jr, Bochner BS, Capogrossi MC, Zweier JL: Hydrogen peroxide and superoxide modulate leukocyte adhesion molecule expression and leukocyte endothelial adhesion. Biochim Biophys Acta 1310: 251-259, 1996
34. Shingu M, Nonaka S, Nishimukai H, Nobunaga M, Kitamura H, Tomo-Oka K: Activation of complement in normal serum by hydrogen peroxide and hydrogen peroxide-related oxygen radicals produced by activated neutrophils. Clin Exp Immunol 90: 72-78, 1992
35. Vogt W, Damerau B, von Zabern I, Nolte R, Brunahl D: Non-enzymic activation of the fifth component of human complement, by oxygen radicals. Some properties of the activation product, C5b-like C5. Mol Immunol 26: 1133-1142, 1989
36. Chenoweth DE: Anaphylatoxin formation in extracorporal circuits. Complement 3: 152-165, 1986
37. Weisman HF, Bartow T, Leppo MK, Marsh HCJ, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT: Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146-151, 1990
38. Mulligan MS, Yeh CG, Rudolph AR, Ward PA: Protective effects of sCR1 in complement- and neutrophil-mediated tissue injury. J Immunol 148: 1479-1485, 1992
39. Homeister JW, Satoh PS, Kilgore KS, Luechesi BR: Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart. J Immunol 150: 1055-1064, 1993
40. Finn A, Morgan BP, Rebuck N, Klein N, Rogers CA, Hibbs M, Elliott M, Shore DF, Evans TW, Strobel S, Moat N: Effects of inhibition of complement activation using recombinant soluble complement receptor 1 on neutrophil CD11b/CD18 and L-selectin expression and release of interleukin-8 and elastase in simulated cardiopulmonary bypass. J Thorac Cardiovasc Surg 111: 451-459, 1996
41. Cheung AK, Parker CJ, Hohnholt M: Soluble complement receptor type 1 inhibits complement activation induced by hemodiaiysis membranes in vitro. Kidney Int 46: 1680-1687, 1994
42. Vogt W, Zimmermann B, Hesse D, Nolle R: Activation of the fifth component of human complement, CS, without cleavage, by methionine oxidizing agents. Mol Imrnunol 29: 251-256, 1992
43. Vogt W, Hesse D: Activation of the fifth component of human complement by oxygen-derived free radicals, and by methionine oxidizing agents: A comparison. Immunobiology 184: 384-391, 1992
44. Vogt W, Hesse D: Oxidants generated by the myeloperoxidasehalide system activate the fifth component of human complement, C5. Immunobiology 192: 1-9, 1994
45. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 320: 365-376, 1989
46. Vogt W: Oxidation of methionyl residues in proteins: Tools, targets, and reversal. Free Radic Biol Med 18: 93-105, 1995
47. Niculescu F, Rus H, Shin ML: Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes. J Biol Chem 269: 4417-4423, 1994
48. Hogasen AKM, Würzner R, Abrahamsen TG, Dierich MP: Human polymorphonuclear leukocytes store large amounts of terminal complement components C7 and C6, which may be released on stimulation. J Immunol 154: 4734-4740, 1995
49. Wang C, Barbashov S, Jack RM, Barrett T, Weller PF, Nicholson-Weller A: Hemolytically inactive C5b67 complex: An agonist of polymorphonuclear leukocytes. Blood 85: 2570-2578, 1995
50. Wang C, Gerard NP, Nicholson-Weller A: Signaling by hemolytically inactive C5b67, an agonist of polymorphonuclear leukocytes. J Immunol 156: 786-792, 1996
51. Vogt W, von Zabern I, Hesse D, Nolte R, Haller Y: Generation of an activated form of human C5 (C5b-like C5) by oxygen radicals. Immunol Lett 14: 209-215, 1986
52. Discipio RG, Daffern PJ, Kawahara M, Pike R, Travis J, Hugli TE: Cleavage of human complement component C5 by cysteine proteinases from Porphyromonas (Bacteroides) gingivalis. Prior oxidation augments proteinase digestion of CS. Immunology 87: 660-667, 1996
53. Foreman KE, Glovsky MM, Warner RL, Horvath SJ, Ward PA: Comparative effect of C3a and C5a on adhesion molecule expression on neutrophils and endothelial cells. Inflammation 20: 1-9, 1996